单细胞分析对霍奇金淋巴瘤生物学的新见解
本文综述单细胞技术(单细胞RNA测序与多重成像)在淋巴瘤研究中的应用,重点以经典霍奇金淋巴瘤(CHL)的肿瘤微环境(TME)为范例,阐述其在解析细胞异质性、细胞亚群与细胞间交互方面的进展。所描述技术适用于外周血、新鲜组织及福尔马林固定样本,有望加速新型免疫治疗生物标志物的发现,并作为未来基于生物标志物指导治疗选择的检测平台。
要点
- 单细胞技术可在单细胞分辨率下解析淋巴瘤细胞异质性与TME细胞组成。
- CHL的TME中肿瘤细胞稀少而免疫细胞众多,患者间与患者内变异显著,是研究范例。
- 单细胞技术适用于外周血、新鲜组织及福尔马林固定样本,有望用于免疫治疗生物标志物发现。
核心结论
- 单细胞技术为理解淋巴瘤细胞异质性、TME组成及细胞间交互提供了有力工具,并有望加速新型免疫治疗生物标志物的发现及作为基于生物标志物指导治疗选择的检测平台。
研究设计与样本
- 本文为综述,检索范围未在原文中具体报告。
主要发现
- 单细胞RNA测序可界定恶性细胞分化状态及推测细胞起源的异质性,并描述TME的组成与细胞亚群。
- 多重成像技术为描述不同淋巴瘤实体中的细胞交互增加了新维度。
- CHL因肿瘤细胞稀少、非恶性免疫细胞众多且患者间与患者内变异显著,可作为研究范例。
关键数值与推荐
- 原文未报告具体标准与数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence and rapid development of single-cell technologies mark a paradigm shift in cancer research. Various technology implementations represent powerful tools to understand cellular heterogeneity, identify minor cell populations that were previously hard to detect and define, and make inferences about cell-to-cell interactions at single-cell resolution. Applied to lymphoma, recent advances in single-cell RNA sequencing have broadened opportunities to delineate previously underappreciated heterogeneity of malignant cell differentiation states and presumed cell of origin, and to describe the composition and cellular subsets in the ecosystem of the tumor microenvironment (TME). Clinical deployment of an expanding armamentarium of immunotherapy options that rely on targets and immune cell interactions in the TME emphasizes the requirement for a deeper understanding of immune biology in lymphoma. In particular, classic Hodgkin lymphoma (CHL) can serve as a study paradigm because of its unique TME, featuring infrequent tumor cells among numerous nonmalignant immune cells with significant interpatient and intrapatient variability. Synergistic to advances in single-cell sequencing, multiplexed imaging techniques have added a new dimension to describing cellular cross talk in various lymphoma entities. Here, we comprehensively review recent progress using novel single-cell technologies with an emphasis on the TME biology of CHL as an application field. The described technologies, which are applicable to peripheral blood, fresh tissues, and formalin-fixed samples, hold the promise to accelerate biomarker discovery for novel immunotherapeutic approaches and to serve as future assay platforms for biomarker-informed treatment selection, including immunotherapies.
引用
- Aoki T, Steidl C. Novel insights into Hodgkin lymphoma biology by single-cell analysis. Blood. 2023. PMID: 36548960. doi:10.1182/blood.2022017147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。